An Authorized Representative (EU Representative) is a natural or legal person established within the European Union who has received a written mandate from a manufacturer to act on their behalf in carrying out specified regulatory tasks for a medical device or in vitro diagnostic medical device, particularly when the manufacturer is based outside the EU. In practice, the EU Authorized Representative serves as a central interface between the manufacturer, competent authorities, and market surveillance bodies—making it a frequently audited component of the European compliance architecture.
The term is primarily known from EU medical device regulation and is closely linked to market placement, supply chain responsibility, and regulatory communication. For sponsors, CROs, and manufacturing teams, it is essential to clearly distinguish the Authorized Representative from the importer and the distributor, as roles and obligations are distributed differently.
Legal Classification, Tasks, and Differentiation
The obligation to appoint an EU Authorized Representative specifically affects manufacturers based outside the EU who place or make products available on the EU market. The Authorized Representative must be established in an EU Member State and possess a formal mandate (written authorization) defining the scope and limits of their tasks. Without a clear mandate text, ambiguities may arise during audits or regulatory inquiries, such as who is authorized to submit which documents or who must respond within specified deadlines.
In practice, the EU Authorized Representative is often involved as early as the planning phase of a market launch to structure technical documentation, vigilance processes, and communication channels with authorities. For medical devices with CE marking, their role regularly becomes visible during conformity assessment and subsequent market surveillance.
Specific tasks are derived from the mandate as well as relevant EU legal acts. Typically, the role profile includes, among other things, the readiness to provide documents or information on conformity upon the reasoned request of a competent authority. Support in communicating incidents and corrective actions is also vital, particularly when deadlines must be met.
Operationally, this often means: documented processes for receiving and forwarding regulatory correspondence, a defined escalation chain to the manufacturer, and the ability to make relevant parts of the technical documentation quickly retrievable. In mature quality management systems, these interfaces are mapped as SOPs and are traceable in an audit trail.
A common practical error is the conflation of roles within the supply chain. The Authorized Representative acts on behalf of the manufacturer based on the mandate. In contrast, the importer introduces products from a third country into the EU supply chain and has its own obligations, such as verifying labeling and documentation. Distributors, in turn, make products available within the EU and must also fulfill defined due diligence obligations.
Differentiation from Importer and Distributor
For companies, it may seem efficient to bundle multiple roles with a single service provider. However, from a regulatory perspective, it must be ensured that responsibilities, processes, and liability are clearly separated and documented. Inspections specifically verify whether responsible parties actually fulfill their tasks or are merely appointed “on paper.”
Relevance for Clinical Trials and the Post-Market Phase
Even though the Authorized Representative role originates primarily from the medical device context, it has indirect significance for clinical evaluations and clinical trials of medical devices because many regulatory communication and documentation obligations in the EU are tied to an EU-based point of contact. In the post-market phase, the EU Authorized Representative is frequently involved when market surveillance authorities request information on vigilance cases, Field Safety Corrective Actions (FSCAs), or recalls.
For CROs supporting manufacturers in clinical evidence generation, it is relevant to understand the contact structures: Who responds to regulatory letters? Who is authorized to release documents? And how is it ensured that information from clinical data collection is correctly transferred into the post-market surveillance system?
Typical Risks and Common Practical Errors
- Unclear scope of mandate: Missing or overly generic authorization leads to delays in responding to regulatory inquiries.
- Lack of process integration: The EU Authorized Representative is not integrated into CAPA, vigilance, or complaint processes.
- Documentation gaps: Communication channels, responsibilities, and handovers are not traceably documented.
- Role confusion: Importer and Authorized Representative tasks are not clearly separated.
These points are particularly critical because deviations in market surveillance can lead to formal measures—ranging from conditions to restrictions on the availability of a product.
For project teams, it is recommended to create a brief role map even before an audit or regulatory inquiry: Which inquiries go to the Authorized Representative, which go directly to the manufacturer, and which go to the importer or distributor? A pragmatic approach is a “Contact-and-Document Map” that brings together responsible parties, deadlines, document locations (e.g., technical documentation, vigilance files), and approval processes. This helps reduce delays in critical situations, such as a reportable incident or a short-notice market surveillance inspection.
Regulatory References (Selection)
- EU Regulation (EU) 2017/745 on Medical Devices (MDR)
- EU Regulation (EU) 2017/746 on In Vitro Diagnostic Medical Devices (IVDR)
- Guidelines on market surveillance and vigilance (e.g., MDCG guidance)
FAQ
When does a manufacturer need an Authorized Representative?
Generally, when the manufacturer is based outside the EU and wishes to make medical devices or in vitro diagnostic medical devices available in the EU. The EU Authorized Representative must be appointed and contractually mandated before market access.
Can the Authorized Representative also be the importer?
This can occur organizationally, but it is only properly implementable if the obligations of both roles are clearly separated, documented, and fulfilled in practice. Audits pay particular attention to this separation.
Is the Authorized Representative responsible for the technical documentation?
Primary responsibility remains with the manufacturer. However, the EU Authorized Representative must be able to respond to regulatory inquiries and provide certain documents or information on conformity—depending on the mandate and the legal situation.